NDRA — ENDRA Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $5.35m
- $4.21m
Annual cashflow statement for ENDRA Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.3 | -11.7 | -11.2 | -13.2 | -10.1 |
| Depreciation | |||||
| Non-Cash Items | 4.04 | 2.4 | 1.24 | 1.34 | 1.31 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.598 | -1.52 | -1.25 | -1.02 | -0.923 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -8.59 | -10.7 | -11.1 | -12.8 | -9.55 |
| Capital Expenditures | -0.044 | -0.075 | -0.045 | -0.203 | -0.034 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | 0.009 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.044 | -0.075 | -0.045 | -0.203 | -0.025 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 8.34 | 11.9 | 13.4 | 8.4 | 7.52 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.297 | 1.05 | 2.23 | -4.57 | -2.06 |